Search for dissertations about: "chronic myeloid leukemia CML"
Showing result 6 - 10 of 32 swedish dissertations containing the words chronic myeloid leukemia CML.
-
6. Myeloid-Derived Suppressor Cells and Other Immune Escape Mechanisms in Chronic Leukemia
Abstract : Chronic myeloid leukemia (CML) is characterized by the Philadelphia chromosome, a minute chromosome that leads to the creation of the fusion gene BCR/ABL and the transcription of the fusion protein BCR/ABL in transformed cells. The constitutively active tyrosine kinase BCR/ABL confers enhanced proliferation and survival on leukemic cells. READ MORE
-
7. Characterization of Genetic Abnormalities at Disease Progression of Chronic Myeloid Leukemia
Abstract : Chronic myeloid leukemia (CML) is a myeloproliferative disorder associated with the translocation t(9;22)(q34;q11) and progresses from a relatively indolent chronic phase (CP) to an accelerated phase (AP) and finally to the more aggressive blast crisis (BC). The general aim of this thesis was to identify and characterize genetic abnormalities occurring at disease progression of CML using molecular cytogenetic, molecular genetic, and bioinformatic analyses. READ MORE
-
8. Clinical and Genetic studies in Chronic Myeloid Leukaemia
Abstract : This thesis explores strategies to enhance deep molecular response (DMR) rates and treatment-free remission (TFR) eligibility in chronic myeloid leukaemia (CML), investigates factors linked to treatment milestone failures, describes tyrosine kinase inhibitor (TKI) discontinuation outcomes in a population-based cohort, and examines TFR probabilities after a second TKI discontinuation. In paper I we examined data from the Swedish CML registry on 128 CML patients in chronic phase with a reported TKI discontinuation of ≥1 month due to DMR. READ MORE
-
9. Aspects on long-term treatment with tyrosine kinase inhibitors in Chronic myeloid leukemia
Abstract : Chronic myeloid leukemia (CML) is caused by the tyrosine kinase activity of the oncoprotein BCR-ABL. The introduction of tyrosine kinase inhibitors (TKIs) targeting BCR-ABL has profoundly changed the prognosis of CML. Currently, there are three TKIs approved for treatment of CML, imatinib, nilotinib and dasatinib. READ MORE
-
10. Targeting NOX2 in cancer
Abstract : Reactive oxygen species (ROS) are short-lived, toxic derivatives of oxygen that are produced during mitochondrial respiration and by NADPH oxidases (NOX). By enzymatically generating ROS, the myeloid cell NOX2 plays a critical role in defense against bacteria and other microorganisms. READ MORE